Suggestions
Augusto Carlos Carlos Pellarini Seguí
CFO | M&A | Angel Investor | Venture Capital | Early Stage Startup Advisor | Enterprise Valuation Expert | Growth Strategy
Augusto Carlos P. is the Head of Finance and Administration (Advisor) at SAMU First Response. He has over 25 years of experience in corporate finance, strategy, valuations, and mergers and acquisitions (M&A). He studied at IESE Business School, which is affiliated with the University of Navarra. His extensive background suggests a strong expertise in financial management and strategic planning within organizations.
Highlights
🚀 Sangamo Therapeutics, Inc. has exciting news! The Q2 2024 financial results will be released on August 6. I hope to get a great updated into the innovative work in #genomicmedicine. It goes beyond numbers, symbolizing a transformative potential in the field.
The commitment of Sangamo Therapeutics, Inc. in addressing critical #neurologicaldiseases through pioneering #geneditingtechnology is truly inspiring. Their use of #zincfinger #epigenetic #regulators and advancements in the #capsid discovery platform showcase their dedication to pushing boundaries in treatment options. #ZFP #ZiFi #genediting #gentherapy Eagerly awaiting updates on strategic direction and the promising pipeline of programs led by Sandy Macrae, MRCP PhD and his team. The hope for insights on #partnering #deals adds to the excitement!
For all intrigued by the future of #geneditingmedicine and the vast potential of #genomictherapies, mark your calendars for this essential event. 🌟 Here is the link https://lnkd.in/eCkt9BUX
Who's been following the positive news from Pfizer on July 24, 2024, regarding the Phase III data on hemophilia A? Sangamo Therapeutics, Inc. has seen a remarkable uptake of its stock $SGMO this past week, with the share price up by +115.84% (+0.46 )! The total volume of shares traded last week reached 431,779,193 according to Sangamo Therapeutics, Inc.'s webpage. Will we see more of this trend? Many thanks to Alex Philippidis for the insightful summary on Sangamo in his new edition of #Stockwatch post from July 26, 2024: https://lnkd.in/eryxtEx6. Could it be that the #GeneTherapy community is finally deciphering the developments in #CRISPR and #ZincFinger? #GenEditing
